LBRX Debt To Assets from 2010 to 2026

LBRX Stock   21.38  2.02  10.43%   
LB Pharmaceuticals Debt To Assets yearly trend continues to be fairly stable with very little volatility. Debt To Assets will likely drop to 0.12 in 2026. During the period from 2010 to 2026, LB Pharmaceuticals Debt To Assets regression line of annual values had r-squared of  0.54 and arithmetic mean of  0.89. View All Fundamentals
 
Debt To Assets  
First Reported
2010-12-31
Previous Quarter
0.13
Current Value
0.12
Quarterly Volatility
0.43982178
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check LB Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among LB Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 800, Net Interest Income of 2.1 M or Interest Income of 2.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. LBRX financial statements analysis is a perfect complement when working with LB Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with LBRX Stock
Check out the analysis of LB Pharmaceuticals Correlation against competitors.

Latest LB Pharmaceuticals' Debt To Assets Growth Pattern

Below is the plot of the Debt To Assets of LB Pharmaceuticals Common over the last few years. It is LB Pharmaceuticals' Debt To Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in LB Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Debt To Assets10 Years Trend
Slightly volatile
   Debt To Assets   
       Timeline  

LBRX Debt To Assets Regression Statistics

Arithmetic Mean0.89
Geometric Mean0.66
Coefficient Of Variation49.59
Mean Deviation0.36
Median1.12
Standard Deviation0.44
Sample Variance0.19
Range1.0132
R-Value(0.74)
Mean Square Error0.09
R-Squared0.54
Significance0.0008
Slope(0.06)
Total Sum of Squares3.10

LBRX Debt To Assets History

2026 0.12
2025 0.13
2023 0.11

About LB Pharmaceuticals Financial Statements

LB Pharmaceuticals investors use historical fundamental indicators, such as LB Pharmaceuticals' Debt To Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in LB Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Debt To Assets 0.13  0.12 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for LBRX Stock Analysis

When running LB Pharmaceuticals' price analysis, check to measure LB Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LB Pharmaceuticals is operating at the current time. Most of LB Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of LB Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LB Pharmaceuticals' price. Additionally, you may evaluate how the addition of LB Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.